%PDF-1.4
%
163 0 obj
<>
endobj
162 0 obj
<>stream
StampPDF Batch 2.7 for Solaris - SPDF 1045
2012-08-01T17:14:42Z
2012-09-05T20:31-07:00
2012-09-05T20:31-07:00
XPP
application/pdf
uuid:1695d4a6-1dd2-11b2-0a00-c009271c8e00
uuid:1695d4ab-1dd2-11b2-0a00-0bf600000000
dc:creator
dc:title
dc:description
endstream
endobj
161 0 obj
<>
endobj
159 0 obj
<>
endobj
150 0 obj
<>
endobj
166 0 obj
<>
endobj
114 0 obj
<>
endobj
117 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageB]/XObject<>>>/Rotate 0/TrimBox[9 9 594 792]/Type/Page>>
endobj
113 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageB]/XObject<>>>/Rotate 0/TrimBox[9 9 594 792]/Type/Page>>
endobj
172 0 obj
<>stream
q
360 0 0 137 129 259 cm
/Im0 Do
Q
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
7.5 0 0 7.5 68.625 720 Tm
[(and)-273.5 (outcome)-273.5 (of)-273.5 (treatment)-273.5 (with)-273.5 (warfarin)-273.5 (in)-273.5 (patients)-273.5 (with)-273.5 (non-valvar)-273.5 (atrial)]TJ
0 -1.2 TD
[(fibrillation:)-373.1 (a)-373.1 (record)-373.1 (linkage)-373.1 (study)-373.1 (in)-373.1 (a)-373.1 (large)-373.1 (British)-373.1 (population.)]TJ
/T1_1 1 Tf
26.8681 0 Td
(Heart)Tj
/T1_0 1 Tf
(.)Tj
-26.8681 -1.2 Td
[(2005;91:472\226)-119.7 (477.)]TJ
-1.75 -1.2 Td
[(35.)-500 (Wallentin)-409.5 (L,)-409.5 (Yusuf)-409.5 (S,)-409.5 (Ezekowitz)-409.5 (MD,)-409.5 (Alings)-409.5 (M,)-409.5 (Flather)-409.5 (M,)-409.5 (Franzosi)]TJ
1.75 -1.2 Td
[(MG,)-297.7 (Pais)-297.7 (P,)-297.7 (Dans)-297.7 (A,)-297.7 (Eikelboom)-297.7 (J,)-297.7 (Oldgren)-297.7 (J,)-297.7 (Pogue)-297.7 (J,)-297.7 (Reilly)-297.7 (PA,)-297.7 (Yang)]TJ
T*
[(S,)-340.9 (Connolly)-340.9 (SJ;)-340.9 (RE-LY)-340.9 (Investigators.)-340.9 (Efficacy)-340.9 (and)-340.9 (safety)-340.9 (of)-340.9 (dabigatran)]TJ
T*
[(compared)-439 (with)-439 (warfarin)-439 (at)-439 (different)-439 (levels)-439 (of)-439 (international)-439 (normalised)]TJ
T*
[(ratio)-298.9 (control)-298.9 (for)-298.9 (stroke)-298.9 (prevention)-298.9 (in)-298.9 (atrial)-298.9 (fibrillation:)-298.9 (an)-298.9 (analysis)-298.9 (of)-298.9 (the)]TJ
T*
[(RE-LY)-333 (trial.)]TJ
/T1_1 1 Tf
5.4709 0 Td
(Lancet.)Tj
/T1_0 1 Tf
3.305 0 Td
(2010;376:975\226983.)Tj
-10.5259 -1.2 Td
[(36.)-500 (van)-237.1 (Ryn)-237.1 (J,)-237.1 (Stangier)-237.1 (J,)-237.1 (Haertter)-237.1 (S,)-237.1 (Liesenfeld)-237.1 (K-H,)-237.1 (Wienen)-237.1 (W,)-237.1 (Feuring)-237.1 (M,)]TJ
1.75 -1.2 Td
[(Clemens)-251.5 (A.)-251.5 (Dabigatran)-251.5 (etexilate:)-251.5 (a)-251.5 (novel,)-251.5 (reversible,)-251.5 (oral)-251.5 (direct)-251.5 (thrombin)]TJ
T*
[(inhibitor:)-508.3 (interpretation)-508.3 (of)-508.3 (coagulation)-508.3 (assays)-508.3 (and)-508.3 (reversal)-508.3 (of)-508.3 (antico-)]TJ
T*
[(agulant)-333 (activity.)]TJ
/T1_1 1 Tf
6.8599 0 Td
[(Thromb)-333 (Haemost)]TJ
/T1_0 1 Tf
[(.)-333 (2010;103:1116)-119.7 (\2261127.)]TJ
-8.6099 -1.2 Td
[(37.)-500 (Eerenberg)-368.6 (ES,)-368.6 (Kamphuisen)-368.6 (PW,)-368.6 (Sijpkens)-368.6 (MK,)-368.6 (Meijers)-368.6 (JC,)-368.6 (Bu)416.6 (\250)-83.3 (ller)-368.6 (HR,)]TJ
1.75 -1.2 Td
[(Levi)-251.1 (M.)-251.1 (Reversal)-251.1 (of)-251.1 (rivaroxaban)-251.1 (and)-251.1 (dabigatran)-251.1 (by)-251.1 (prothrombin)-251.1 (complex)]TJ
T*
[(concentrate:)-240.2 (a)-240.2 (randomized,)-240.2 (placebo-controlled,)-240.2 (crossover)-240.2 (study)-240.2 (in)-240.1 (healthy)]TJ
T*
(subjects.)Tj
/T1_1 1 Tf
3.805 0 Td
(Circulation)Tj
/T1_0 1 Tf
[(.)-333 (2011;124:1573\2261579.)]TJ
-5.555 -1.2 Td
[(38.)-500 (Cotton)-541.3 (BA,)-541.3 (McCarthy)-541.3 (JJ,)-541.3 (Holcomb)-541.3 (JB.)-541.3 (Acutely)-541.3 (injured)-541.3 (patients)-541.3 (on)]TJ
1.75 -1.2 Td
(dabigatran.)Tj
/T1_1 1 Tf
4.804 0 Td
[(N)-333 (Engl)-333 (J)-333 (Med)]TJ
/T1_0 1 Tf
[0.1 (.)-333 (2011;365:2039)-119.7 (\2262040.)]TJ
-6.5539 -1.2 Td
[(39.)-500 (Freeman)-450.8 (JV,)-450.8 (Zhu)-450.8 (RP,)-450.8 (Owens)-450.8 (DK,)-450.8 (Garber)-450.8 (AM,)-450.8 (Hutton)-450.8 (DW,)-450.8 (Go)-450.8 (AS,)]TJ
1.75 -1.2 Td
[(Wang)-300.4 (PJ,)-300.4 (Turakhia)-300.4 (MP.)-300.4 (Cost-effectiveness)-300.4 (of)-300.4 (dabigatran)-300.4 (compared)-300.4 (with)]TJ
T*
[(warfarin)-525.8 (for)-525.8 (stroke)-525.8 (prevention)-525.8 (in)-525.8 (atrial)-525.8 (fibrillation.)]TJ
/T1_1 1 Tf
22.3153 0 Td
[(Ann)-525.8 (Intern)-525.8 (Med)]TJ
/T1_0 1 Tf
[0.1 (.)]TJ
-22.3153 -1.2 Td
(2011;154:1\22611.)Tj
-1.75 -1.2 Td
[(40.)-500 (Pink)-279.2 (J,)-279.2 (Lane)-279.2 (S,)-279.2 (Pirmohamed)-279.2 (M,)-279.2 (Hughes)-279.2 (DA.)-279.2 (Dabigatran)-279.2 (etexilate)-279.2 (versus)]TJ
1.75 -1.2 Td
[(warfarin)-272.7 (in)-272.7 (management)-272.7 (of)-272.7 (non-valvular)-272.7 (atrial)-272.7 (fibrillation)-272.7 (in)-272.7 (UK)-272.7 (context:)]TJ
T*
[(quantitative)-275 (benefit-harm)-275 (and)-275 (economic)-275 (analyses.)]TJ
/T1_1 1 Tf
20.232 0 Td
(BMJ.)Tj
/T1_0 1 Tf
2.413 0 Td
(2011;343:d6333.)Tj
-24.395 -1.2 Td
[(41.)-500 (Shah)-514 (SV,)-514 (Gage)-514 (BF.)-514 (Cost-effectiveness)-514 (of)-514 (dabigatran)-514 (for)-514 (stroke)-514 (pro-)]TJ
1.75 -1.2 Td
[(phylaxis)-333 (in)-333 (atrial)-333 (fibrillation.)]TJ
/T1_1 1 Tf
12.0818 0 Td
(Circulation)Tj
/T1_0 1 Tf
[(.)-333 (2011;123:2562\2262570.)]TJ
-13.8318 -1.2 Td
[(42.)-500 (Sorensen)-237.1 (S,)-237.1 (Kansal)-237.1 (A,)-237.1 (Connolly)-237.1 (S,)-237.1 (Peng)-237.1 (S,)-237.1 (Linnehan)-237.1 (J,)-237.1 (Bradley-Kennedy)]TJ
1.75 -1.2 Td
[(C,)-309.8 (Plumb)-309.8 (J.)-309.8 (Cost-effectiveness)-309.8 (of)-309.8 (dabigatran)-309.8 (etexilate)-309.8 (for)-309.8 (the)-309.8 (prevention)]TJ
T*
[(of)-345.5 (stroke)-345.5 (and)-345.5 (systemic)-345.5 (embolism)-345.5 (in)-345.5 (atrial)-345.5 (fibrillation:)-345.5 (a)-345.5 (Canadian)-345.5 (payer)]TJ
T*
(perspective.)Tj
/T1_1 1 Tf
5.137 0 Td
[(Thromb)-333 (Haemost)]TJ
/T1_0 1 Tf
[(.)-333 (2011;105:908)-119.7 (\226919.)]TJ
-6.8869 -1.2 Td
[(43.)-500 (Spackman)-536.4 (E,)-536.4 (Burch)-536.4 (J,)-536.4 (Faria)-536.4 (R,)-536.4 (Corbacho)-536.4 (B,)-536.4 (Fox)-536.4 (D,)-536.4 (Woolacott)-536.4 (N.)]TJ
/T1_1 1 Tf
1.75 -1.2 Td
[(Dabigatran)-235.6 (Etexilate)-235.6 (for)-235.6 (the)-235.6 (Prevention)-235.6 (of)-235.6 (Stroke)-235.6 (and)-235.6 (Systemic)-235.6 (Embolism)]TJ
T*
[(in)-522 (Atrial)-522 (Fibrillation:)-522 (Evidence)-522 (Review)-522 (Group)-522 (Report.)]TJ
/T1_0 1 Tf
23.9028 0 Td
[(York,)-522 (United)]TJ
-23.9028 -1.2 Td
[(Kingdom:)-365.9 (National)-365.9 (Institute)-365.9 (for)-365.9 (Health)-365.9 (and)-365.9 (Clinical)-365.9 (Excellence,)-365.9 (Centre)]TJ
T*
[(for)-333 (Health)-333 (Economics;)-333 (2011.)]TJ
-1.75 -1.2 Td
[(44.)-500 (Freeman)-236.4 (JV,)-236.4 (Turakhia)-236.4 (MP.)-236.4 (Dabigatran)-236.4 (compared)-236.4 (with)-236.4 (warfarin)-236.4 (for)-236.4 (stroke)]TJ
1.75 -1.2 Td
[(prevention)-333 (in)-333 (atrial)-333 (fibrillation.)]TJ
/T1_1 1 Tf
12.9698 0 Td
[(Ann)-333 (Intern)-333 (Med)]TJ
/T1_0 1 Tf
[0.1 (.)-333 (2011;154:570)-119.7 (\226571.)]TJ
-14.7198 -1.2 Td
[(45.)-500 (Beasley)-292.8 (BN,)-292.8 (Unger)-292.8 (EF,)-292.8 (Temple)-292.8 (R.)-292.8 (Anticoagulant)-292.8 (options:)-292.8 (why)-292.8 (the)-292.8 (FDA)]TJ
1.75 -1.2 Td
[(approved)-406.8 (a)-406.8 (higher)-406.8 (but)-406.8 (not)-406.8 (a)-406.8 (lower)-406.8 (dose)-406.8 (of)-406.8 (dabigatran.)]TJ
/T1_1 1 Tf
23.2022 0 Td
[(N)-406.8 (Engl)-406.8 (J)-406.8 (Med)]TJ
/T1_0 1 Tf
[-0.1 (.)]TJ
-23.2021 -1.2 Td
[(2011;364:1788)-119.7 (\2261790.)]TJ
0.0201 Tc -1.75 -1.2 Td
[(4)20.1 (6)20.1 (.)-479.9 (Summary)-396.2 (Minutes)-396.2 (of)-396.2 (the)-396.2 (Cardiovascular)-396.2 (and)-396.2 (Renal)-396.2 (Drugs)-396.2 (Advisory)]TJ
0.02609 Tc 1.75 -1.2 Td
[(Committee)-592.1 (\(September)-592.1 (20,)-592.1 (2010\).)-592.1 (http://www.fda.gov/downloads/)]TJ
0.0352 Tc T*
(Advisory%20Committees/CommitteesMeetingMaterials/%20Drugs/)Tj
0.0239 Tc T*
(CardiovascularandRenalDrugs%20AdvisoryCommittee/UCM236322.)Tj
0.0201 Tc T*
[(pdf.)-353 (Accessed)-353 (November)-353 (15,)-353 (2011.)]TJ
0 Tc -1.75 -1.2 Td
[(47.)-500 (US)-240.9 (Department)-240.9 (of)-240.9 (Health)-240.9 (&)-240.9 (Human)-240.9 (Services,)-240.9 (US)-240.9 (Food)-240.9 (and)-240.9 (Drug)-240.9 (Admin-)]TJ
1.75 -1.2 Td
[(istration.)-234.1 (FDA)-234.1 (Drug)-234.1 (Safety)-234.1 (Communication:)-234.1 (safety)-234.1 (review)-234.1 (of)-234.1 (post-market)]TJ
T*
[(reports)-365.5 (of)-365.5 (serious)-365.5 (bleeding)-365.5 (events)-365.5 (with)-365.5 (the)-365.5 (anticoagulant)-365.5 (Pradaxa)-365.5 (\(dab-)]TJ
0.02769 Tc T*
[(igatran)-580.3 (etexilate)-580.3 (mesylate\).)-580.3 (http://www.fda.gov/Drugs/DrugSafety/)]TJ
0 Tc T*
[(ucm282724.htm#data.)-333 (Accessed)-333 (December)-333 (7,)-333 (2011.)]TJ
-1.75 -1.2 Td
[(48.)-500 (European)-233.3 (Medicines)-233.3 (Agency)-233.3 (updates)-233.3 (on)-233.3 (safety)-233.3 (of)-233.3 (Pradaxa)-233.3 ([news)-233.3 (release].)]TJ
1.75 -1.2 Td
[(London,)-350.8 (United)-350.8 (Kingdom:)-350.8 (European)-350.8 (Medicines)-350.8 (Agency;)-350.8 (November)-350.8 (18,)]TJ
0.008 Tc T*
[(2011.)-547.3 (http://www.ema.europa.eu/docs/en_GB/document_library/Press_)]TJ
-0.0197 Tc T*
[(release/2011/11/WC500117818.pdf.)-313.3 (Accessed)-313.3 (December)-313.3 (6,)-313.3 (2011.)]TJ
0 Tc -1.75 -1.2 Td
[(49.)-500 (Australian)-414.8 (Government)-414.8 (Department)-414.8 (of)-414.8 (Health)-414.8 (and)-414.8 (Ageing)-414.8 (Therapeutic)]TJ
1.75 -1.2 Td
[(Goods)-289.8 (Administration.)-289.8 (Dabigatran)-289.8 (\(Pradaxa\):)-289.8 (risk)-289.8 (of)-289.8 (bleeding)-289.8 (relating)-289.8 (to)]TJ
0.0163 Tc 34.4 68.4 Td
[(use.)-568.9 (http://www.tga.gov.au/safety/alerts-medicine-dabigatran-111005.)]TJ
0 Tc 0 -1.2167 TD
[(htm.)-333 (Accessed)-333 (December)-333 (7,)-333 (2011.)]TJ
-1.75 -1.2167 Td
[(50.)-500 (Australian)-414.8 (Government)-414.8 (Department)-414.8 (of)-414.8 (Health)-414.8 (and)-414.8 (Ageing)-414.8 (Therapeutic)]TJ
1.75 -1.2167 Td
[(Goods)-276.1 (Administration.)-276.1 (Dabigatran)-276.1 (\(Pradaxa\))-276.1 (&)-276.1 (the)-276.1 (risk)-276.1 (of)-276.1 (bleeding:)-276.1 (new)]TJ
T*
[(recommendations)-234.8 (for)-234.8 (monitoring)-234.8 (kidney)-234.8 (function.)-234.9 (http://www.tga.gov.au/)]TJ
0.00571 Tc T*
[(safety/alerts-medicine-dabigatran-111103.htm.)-558.3 (Accessed)-558.3 (December,)-558.3 (7)]TJ
0 Tc T*
(2011.)Tj
-1.75 -1.2167 Td
[(51.)-500 (Wann)-246.2 (LS,)-246.2 (Curtis)-246.2 (AB,)-246.2 (January)-246.2 (CT,)-246.2 (Ellenbogen)-246.2 (KA,)-246.2 (Lowe)-246.2 (JE,)-246.2 (Estes)-246.2 (NAM)]TJ
1.75 -1.2167 Td
[(3rd,)-375 (Page)-375 (RL,)-375 (Ezekowitz)-375 (MD,)-375 (Slotwiner)-375 (DJ,)-375 (Jackman)-375 (WM,)-375 (Stevenson)]TJ
T*
[(WG,)-225.8 (Tracy)-225.8 (CM;)-225.8 (on)-225.8 (behalf)-225.8 (of)-225.8 (the)-225.8 (2006)-225.8 (ACC/AHA/ESC)-225.8 (Guidelines)-225.8 (for)-225.8 (the)]TJ
T*
[(Management)-512.9 (of)-512.9 (Patients)-512.9 (With)-512.9 (Atrial)-512.9 (Fibrillation)-512.9 (Writing)-512.9 (Committee.)]TJ
T*
[(2011)-390.2 (ACCF/AHA/HRS)-390.2 (focused)-390.2 (update)-390.2 (on)-390.2 (the)-390.2 (management)-390.2 (of)-390.2 (patients)]TJ
T*
[(with)-506.4 (atrial)-506.4 (fibrillation)-506.4 (\(updating)-506.4 (the)-506.4 (2006)-506.4 (guideline\):)-506.4 (a)-506.4 (report)-506.4 (of)-506.4 (the)]TJ
T*
[(American)-224.2 (College)-224.2 (of)-224.2 (Cardiology)-224.2 (Foundation/American)-224.2 (Heart)-224.2 (Association)]TJ
T*
[(Task)-322.3 (Force)-322.3 (on)-322.3 (Practice)-322.3 (Guidelines)-322.3 ([published)-322.3 (correction)-322.3 (appears)-322.4 (in)]TJ
/T1_1 1 Tf
27.7841 0 Td
(Cir-)Tj
-27.7841 -1.2167 Td
(culation)Tj
/T1_0 1 Tf
[(.)-333 (2011;124:e173].)]TJ
/T1_1 1 Tf
10.7769 0 Td
(Circulation)Tj
/T1_0 1 Tf
[(.)-333 (2011;123:104)-119.7 (\226123.)]TJ
-12.5269 -1.2167 Td
[(52.)-500 (Patel)-228 (MR,)-228 (Mahaffey)-228 (KW,)-228 (Garg)-228 (J,)-228 (Pan)-228 (G,)-228 (Singer)-228 (DE,)-228 (Hacke)-228 (W,)-228 (Breithardt)]TJ
1.75 -1.2167 Td
[(G,)-344.7 (Halperin)-344.7 (JL,)-344.7 (Hankey)-344.7 (GJ,)-344.7 (Piccini)-344.7 (JP,)-344.7 (Becker)-344.7 (RC,)-344.7 (Nessel)-344.7 (CC,)-344.7 (Paolini)]TJ
T*
[(JF,)-495.1 (Berkowitz)-495.1 (SD,)-495.1 (Fox)-495.1 (KA,)-495.1 (Califf)-495.1 (RM;)-495.1 (ROCKET)-495.1 (AF)-495.1 (Investigators.)]TJ
T*
[(Rivaroxaban)-463.3 (versus)-463.3 (warfarin)-463.3 (in)-463.3 (nonvalvular)-463.3 (atrial)-463.3 (fibrillation.)]TJ
/T1_1 1 Tf
26.4328 0 Td
[(N)-463.3 (Engl)]TJ
-26.4328 -1.2167 Td
[(J)-333 (Med)]TJ
/T1_0 1 Tf
[(.)-333 (2011;365:883\226)-119.7 (891.)]TJ
-1.75 -1.2167 Td
[(53.)-500 (Trial)-263.3 (Results)-263.3 (Center.)-263.3 (Trials)-263.3 (Register)-263.3 (No.)-263.3 (NCT00494871.)-263.3 (http://www.trial)]TJ
0.0072 Tc 1.75 -1.2167 Td
[(resultscenter.org/study12240-ROCKET-J.htm.)-559.8 (Accessed)-559.8 (December)-559.9 (5,)]TJ
0 Tc T*
(2011.)Tj
-1.75 -1.2167 Td
[(54.)-500 (Beasley)-306.8 (N,)-306.8 (Dunnmon)-306.8 (P,)-306.8 (Rose)-306.8 (M.)-306.8 (FDA)-306.8 (Draft)-306.8 (Briefing)-306.8 (Document)-306.8 (for)-306.8 (the)]TJ
0.0231 Tc 1.75 -1.2167 Td
[(Cardiovascular)-575.8 (and)-575.8 (Renal)-575.8 (Drugs)-575.8 (Advisory)-575.8 (Committee)-575.8 (\(CRDAC\).)]TJ
0 Tc T*
[(Clinical)-460.2 (Review:)-460.2 (NDA)-460.2 (202439:)-460.2 (Xarelto)-460.2 (\(rivaroxaban\).)]TJ
-0.0197 Tc 23.3964 0 Td
(http://www.fda.)Tj
-0.0076 Tc -23.3964 -1.2167 Td
(gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/)Tj
0.0295 Tc T*
(CardiovascularandRenalDrugsAdvisory)Tj
0.04919 Tc 17.0311 0 Td
(Committee/ucm270796.pdf.)Tj
0 Tc -17.0311 -1.2167 Td
[(Accessed)-333 (December)-333 (5,)-333 (2011.)]TJ
-1.75 -1.2167 Td
[(55.)-500 (Fleming)-320.5 (TR,)-320.5 (Emerson)-320.5 (SS.)-320.4 (Evaluating)-320.5 (rivaroxaban)-320.4 (for)-320.5 (nonvalvular)-320.5 (atrial)]TJ
1.75 -1.2167 Td
[(fibrillation:)-453.4 (regulatory)-453.4 (considerations.)]TJ
/T1_1 1 Tf
16.0532 0 Td
[(N)-453.4 (Engl)-453.4 (J)-453.4 (Med)]TJ
/T1_0 1 Tf
[(.)-453.4 (2011;365:1557\226)]TJ
-16.0533 -1.2167 Td
(1559.)Tj
-1.75 -1.2167 Td
[(56.)-500 (Connolly)-420.1 (SJ,)-420.1 (Eikelboom)-420.1 (J,)-420.1 (Joyner)-420.1 (C,)-420.1 (Diener)-420.1 (HC,)-420.1 (Hart)-420.1 (R,)-420.1 (Golitsyn)-420.1 (S,)]TJ
1.75 -1.2167 Td
[(Flaker)-340.5 (G,)-340.5 (Avezum)-340.5 (A,)-340.5 (Hohnloser)-340.5 (SH,)-340.5 (Diaz)-340.5 (R,)-340.5 (Talajic)-340.5 (M,)-340.5 (Zhu)-340.5 (J,)-340.5 (Pais)-340.5 (P,)]TJ
T*
[(Budaj)-339.4 (A,)-339.4 (Parkhomenko)-339.4 (A,)-339.4 (Jansky)-339.4 (P,)-339.4 (Commerford)-339.4 (P,)-339.4 (Tan)-339.4 (RS,)-339.4 (Sim)-339.4 (KH,)]TJ
0.01289 Tc T*
[(Lewis)-565.5 (BS,)-565.5 (Van)-565.5 (Mieghem)-565.5 (W,)-565.5 (Lip)-565.5 (GY,)-565.5 (Kim)-565.5 (JH,)-565.5 (Lanas-Zanetti)-565.5 (F,)]TJ
0 Tc T*
[(Gonzalez-Hermosillo)-238.3 (A,)-238.3 (Dans)-238.3 (AL,)-238.3 (Munawar)-238.3 (M,)-238.3 (O\222Donnell)-238.3 (M,)-238.3 (Lawrence)]TJ
T*
[(J,)-448.5 (Lewis)-448.5 (G,)-448.5 (Afzal)-448.5 (R,)-448.5 (Yusuf)-448.5 (S;)-448.5 (AVERROES)-448.5 (Steering)-448.5 (Committee)-448.5 (and)]TJ
T*
[(Investigators.)-287.1 (Apixaban)-287.1 (in)-287.1 (patients)-287.1 (with)-287.1 (atrial)-287.1 (fibrillation.)]TJ
/T1_1 1 Tf
23.5639 0 Td
[(N)-287.1 (Engl)-287.1 (J)-287.1 (Med)]TJ
/T1_0 1 Tf
[-0.1 (.)]TJ
-23.5638 -1.2167 Td
[(2011;364:806)-119.7 (\226)-119.7 (817.)]TJ
-1.75 -1.2167 Td
[(57.)-500 (Olesen)-258.7 (JB,)-258.7 (Lip)-258.7 (GY,)-258.7 (Hansen)-258.7 (ML,)-258.7 (Hansen)-258.7 (PR,)-258.7 (Tolstrup)-258.7 (JS,)-258.7 (Lindhardsen)-258.7 (J,)]TJ
1.75 -1.2167 Td
[(Selmer)-547.7 (C,)-547.7 (Ahlehoff)-547.7 (O,)-547.7 (Olsen)-547.7 (AM,)-547.7 (Gislason)-547.7 (GH,)-547.7 (Torp-Pedersen)-547.7 (C.)]TJ
T*
[(Validation)-291.3 (of)-291.3 (risk)-291.3 (stratification)-291.3 (schemes)-291.3 (for)-291.3 (predicting)-291.3 (stroke)-291.3 (and)-291.3 (throm-)]TJ
T*
[(boembolism)-351.5 (in)-351.5 (patients)-351.5 (with)-351.5 (atrial)-351.5 (fibrillation:)-351.5 (nationwide)-351.5 (cohort)-351.5 (study.)]TJ
/T1_1 1 Tf
T*
(BMJ)Tj
/T1_0 1 Tf
[(.)-333 (2011;342:d124.)]TJ
-1.75 -1.2167 Td
[(58.)-500 (Granger)-282.2 (CB,)-282.2 (Alexander)-282.2 (JH,)-282.2 (McMurray)-282.2 (JJ,)-282.2 (Lopes)-282.2 (RD,)-282.2 (Hylek)-282.2 (EM,)-282.2 (Hanna)]TJ
1.75 -1.2167 Td
[(M,)-433.7 (Al-Khalidi)-433.7 (HR,)-433.7 (Ansell)-433.7 (J,)-433.7 (Atar)-433.7 (D,)-433.7 (Avezum)-433.7 (A,)-433.7 (Bahit)-433.7 (MC,)-433.7 (Diaz)-433.7 (R,)]TJ
T*
[(Easton)-385.2 (JD,)-385.2 (Ezekowitz)-385.2 (JA,)-385.2 (Flaker)-385.2 (G,)-385.2 (Garcia)-385.2 (D,)-385.2 (Geraldes)-385.2 (M,)-385.2 (Gersh)-385.2 (BJ,)]TJ
T*
[(Golitsyn)-326.1 (S,)-326.1 (Goto)-326.1 (S,)-326.1 (Hermosillo)-326.1 (AG,)-326.1 (Hohnloser)-326.1 (SH,)-326.1 (Horowitz)-326.1 (J,)-326.1 (Mohan)]TJ
T*
[(P,)-512.1 (Jansky)-512.1 (P,)-512.1 (Lewis)-512.1 (BS,)-512.1 (Lopez-Sendon)-512.1 (JL,)-512.1 (Pais)-512.1 (P,)-512.1 (Parkhomenko)-512.1 (A,)]TJ
T*
[(Verheugt)-297.3 (FW,)-297.3 (Zhu)-297.4 (J,)-297.4 (Wallentin)-297.3 (L;)-297.3 (ARISTOTLE)-297.3 (Committees)-297.4 (and)-297.3 (Inves-)]TJ
T*
[(tigators.)-515.2 (Apixaban)-515.2 (versus)-515.2 (warfarin)-515.2 (in)-515.2 (patients)-515.2 (with)-515.2 (atrial)-515.2 (fibrillation.)]TJ
/T1_1 1 Tf
T*
[(N)-333 (Engl)-333 (J)-333 (Med)]TJ
/T1_0 1 Tf
[0.1 (.)-333 (2011;365:981\226992.)]TJ
ET
0 0 0 1 K
0.5 w
q 1 0 0 1 313.5 224 cm
0 0 m
234 0 l
S
Q
BT
/T1_0 1 Tf
7.5 0 0 7.5 313.5 215.625 Tm
(K)Tj
-0.0269 Tc 5.5 0 0 5.5 318.7673 215.625 Tm
(EY)Tj
0 Tc 7.5 0 0 7.5 328.2971 215.625 Tm
(W)Tj
-0.0269 Tc 5.5 0 0 5.5 335.2293 215.625 Tm
(ORDS)Tj
-0.0197 Tc 7.5 0 0 7.5 349.3058 215.625 Tm
[(:)-332.6 (AHA)-332.6 (Scientific)-332.6 (Statements)]TJ
/T1_2 1 Tf
0 Tc 10 0 0 10 436.7326 214.625 Tm
(\002)Tj
/T1_0 1 Tf
-0.0197 Tc 7.5 0 0 7.5 445.5911 215.625 Tm
[(atrial)-332.6 (fibrillation)]TJ
/T1_2 1 Tf
0 Tc 10 0 0 10 496.4181 214.625 Tm
(\002)Tj
/T1_0 1 Tf
-0.0197 Tc 7.5 0 0 7.5 505.2766 215.625 Tm
(antithrombotic)Tj
-25.5702 -1.15 Td
(therapy)Tj
/T1_2 1 Tf
0 Tc 10 0 0 10 338.9328 206 Tm
(\002)Tj
/T1_0 1 Tf
-0.0197 Tc 7.5 0 0 7.5 348.2714 207 Tm
[(stroke)-396.6 (prevention)]TJ
/T1_2 1 Tf
0 Tc 10 0 0 10 403.2641 206 Tm
(\002)Tj
/T1_0 1 Tf
-0.0197 Tc 7.5 0 0 7.5 412.6027 207 Tm
(treatment)Tj
/T1_3 1 Tf
0 Tc 10 0 0 10 55.5 751.5 Tm
[(12)-2000 (Stroke)]TJ
/T1_4 1 Tf
7.6671 0 Td
[(October)-333 (2012)]TJ
ET
BT
0 g
/RelativeColorimetric ri
/GS1 gs
/T1_5 1 Tf
9 0 0 9 330.6194 32 Tm
( by guest on September 5, 2012)Tj
0 0 1 rg
/GS1 gs
-11.55499 0 Td
(http://stroke.ahajournals.org/)Tj
0 g
/GS1 gs
-7.55399 0 Td
(Downloaded from )Tj
ET
endstream
endobj
44 0 obj
<>stream
Exif MM * i ( 1 2 ҇i
'
'Adobe Photoshop CS5 Windows 2012:02:09 07:50:21 0221 h n v( ~ v H H Adobe_CM Adobe d
= "
?
3 !1AQa"q2B#$Rb34rC%Scs5&DTdE£t6UeuF'Vfv7GWgw 5 !1AQaq"2B#R3$brCScs4%&5DTdEU6teuFVfv'7GWgw ? *M,mUT`
kZѵck4IJI$RI$I%)$IJI$RI$Q~'ILFVs"14]YBcV_mo,ʚG T[Ev;@}=k7}6{w$Ʈ7k$g7=}J_cYŹ8`;Ad9)A1)I%)$IJLH9
VФU~70TiͱN:bs{56\Z1'OsIEkcqHLjx 876uS$,{Y*k/1Y`
hA+HXvr![OA\HC5.q
hvh[R/?(Ӱ{fe<IMv i ϯivʰJTI%)$IHrjʫҲbeYeGjGߥW?Fe9c`'ibi&? ȣ?GѲ`OEd; h;`QN3OtZ>wޫd|i,`POҟgorJejoڱc=ٴ ex>k7LN=B궰dk>N,[UfN;4Jjzmˬ{$uƷ'
X71=.Z&a>vgH3~qV͕9߽d;SYM͵vkGi?;bV6ۑlZ kjoBYwl Pp~CUY ILcD3hc%Ksl>k?qGC:1s!q~lvs+oEo8zݚc\
v6>Ϣ$JRI$WucI.J?q Y7 ∓ȱ#?>?;n$ oV ɥwJV8O=?hj[?yl7gn I)?4nc IfT,efY&:~.;wG?+> f*MNFޔNݿ*FKGЃ} ?۸ K?+? 02 Eͻ KgМ/@潟INV ɤ: 6 &